Electronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians

被引:13
|
作者
Chan, Alexandre [1 ,2 ]
Yap, Kevin Yi-Lwern [3 ]
Koh, Dorothy [1 ]
Low, Xiu Hui [1 ]
Cheung, Yin Ting [1 ]
机构
[1] Natl Univ Singapore, Dept Pharm, Fac Sci, Singapore 117543, Singapore
[2] Natl Canc Ctr Singapore, Dept Pharm, Singapore, Singapore
[3] Univ Warwick, Inst Digital Healthcare, WMG, Coventry CV4 7AL, W Midlands, England
关键词
oral anticancer drugs; antidepressants; drug-drug interactions; prevalence; co-prescription; TAMOXIFEN; CHEMOTHERAPY; INHIBITORS;
D O I
10.1002/pds.2167
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Electronic drug interaction databases are often utilized in clinical practice to detect for possible drug-drug interactions between drug pairs. It is uncertain, however, whether most of these detections interactions are clinically important in practice. To demonstrate these issues, this study utilized a comprehensive drug-drug interaction( DDI) electronic database to elucidate the prevalence of DDIs at a cancer centre between antidepressants and oral anticancer drugs( ACDs). Methods Drug utilization reports were retrieved to determine the patients who were prescribed with antidepressants oral ACDs between 2006 and 2009 at a cancer center. Medication records of these patients were retrospectively examined using OncoRx, an internet-based oncology-specific database that allows the identification of DDIs. Results Out of 910 users of antidepressants, about one-third( 281 patients, 30.9%) used an oral ACD and an antidepressant concomitantly. From these patients, about one-fifth( 21.0%) had potential DDIs. These patients were users of 17 potentially interacting drug pairs. Ten out of the 17 drug pairs could potentially cause pharmacokinetic interactions, and the rest were pharmacodynamic interactions, with only three out of the 17 drug pairs were clinically documented to cause interacting events. Conclusion The lack of screening conditions may have led to an over detection of DDI combinations by electronic DDI databases. Many of the detected interactions may not deem high significance in clinical practice. This study exposed a major weakness of current electronic DDI databases for detecting oral ACDs and antidepressants DDIs. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:939 / 947
页数:9
相关论文
共 37 条
  • [1] Drug-Drug Interactions between Oral Antiepileptics and Oral Anticancer Drugs: Implications to Clinicians
    Cheung, Yin Ting
    Yap, Kevin Yi-Lwern
    Chui, Wai Keung
    Chan, Alexandre
    EUROPEAN NEUROLOGY, 2010, 64 (02) : 88 - 94
  • [2] Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs
    van Leeuwen, R. W. F.
    Brundel, D. H. S.
    Neef, C.
    van Gelder, T.
    Mathijssen, R. H. J.
    Burger, D. M.
    Jansman, F. G. A.
    BRITISH JOURNAL OF CANCER, 2013, 108 (05) : 1071 - 1078
  • [3] Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions
    Eisenmann, Eric D.
    Talebi, Zahra
    Sparreboom, Alex
    Baker, Sharyn D.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2022, 130 : 23 - 35
  • [4] Prevalence of Drug-Drug Interactions among Epileptic Patients Receiving Antiepileptic Drugs and Oral Anticancer Drugs at a Cancer Centre: A Retrospective Study
    Cheung, Yin Ting
    Chan, Alexandre
    Chui, Wai Keung
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S56 - S56
  • [5] Involvement of Transporters in Intestinal Drug-Drug Interactions of Oral Targeted Anticancer Drugs Assessed by Changes in Drug Absorption Time
    Malnoe, David
    Fardel, Olivier
    Le Corre, Pascal
    PHARMACEUTICS, 2022, 14 (11)
  • [6] Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
    R W F van Leeuwen
    D H S Brundel
    C Neef
    T van Gelder
    R H J Mathijssen
    D M Burger
    F G A Jansman
    British Journal of Cancer, 2013, 108 : 1071 - 1078
  • [7] Drug-Drug Interactions Arising From the Use of Liposomal Vincristine in Combination with Other Anticancer Drugs
    Dawn N. Waterhouse
    Nancy Dos Santos
    Lawrence D. Mayer
    Marcel B. Bally
    Pharmaceutical Research, 2001, 18 : 1331 - 1335
  • [8] Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs
    Waterhouse, DN
    Dos Santos, N
    Mayer, LD
    Bally, MB
    PHARMACEUTICAL RESEARCH, 2001, 18 (09) : 1331 - 1335
  • [9] Real-life drug-drug and herb-drug interactions in outpatients taking oral anticancer drugs: comparison with databases
    Prely, H.
    Herledan, C.
    Caffin, A. G.
    Baudouin, A.
    Larbre, V
    Maire, M.
    Schwiertz, V
    Vantard, N.
    Ranchon, F.
    Rioufol, C.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (03) : 707 - 718
  • [10] Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs
    Subrata Deb
    Robert Hopefl
    DARU Journal of Pharmaceutical Sciences, 2023, 31 : 95 - 105